The effect of platelet-rich plasma on female androgenetic alopecia: A randomized controlled trial - 10/10/20
, Matthew J. Lin, MD a, Hayley M. Leight, MD a, Aaron S. Farberg, MD a, b, Richard L. Torbeck, MD a, William B. Burton, PhD c, Hooman Khorasani, MD aAbstract |
Background |
Platelet-rich plasma (PRP) may be a useful treatment for androgenetic alopecia (AGA), although objective studies are needed.
Objective |
To determine whether PRP injections improve female AGA.
Method |
Prospective randomized controlled trial of 30 women diagnosed with AGA. Patients received subdermal scalp injections of Eclipse system PRP or placebo saline at weeks 0, 4, and 8. Outcome measures were changes in hair density (hair/cm2), hair caliber (mm), and blinded global photographic assessment (improved or not improved) at week 24.
Results |
Blinded global photographic assessment indicated that 57% of patients receiving PRP versus 7% of patients receiving saline improved at week 24 from baseline (P < .01). Compared to baseline, there was improvement in mean density in the PRP group versus the placebo group at week 8 (+71.1 vs −26.7 hairs/cm2; P < .01) and week 24 (+105.9 vs −52.4 hairs/cm2; P < .01). Compared to baseline, there was improvement in mean caliber in the PRP group versus the placebo group at week 8 (+0.0043 vs −0.0034 mm; P < .01) and week 24 (+0.0053 vs −0.0060 mm; P < .01). Adverse effects included headache, scalp tightness, swelling, redness, and postinjection bleeding.
Limitations |
Two patients lost to follow-up.
Conclusions |
PRP with the Eclipse system is a safe and effective intervention for female AGA.
Le texte complet de cet article est disponible en PDF.Key words : androgenetic alopecia, female pattern hair loss, platelet-rich plasma, regenerative medicine
Abbreviations used : AGA, PRP
Plan
| Funding sources: Supported by Eclipse Aesthetics, LLC [Icahn School of Medicine at Mount Sinai Grants and Contracts Office no. 18-1714(0001)]. |
|
| Disclosure: Dr Farberg currently serves on the advisory board of Suneva Medical, Inc. Drs Dubin, Lin, Leight, Torbeck, Burton, and Khorasani have no conflicts of interest to declare. |
|
| IRB approval status: Reviewed and approved by the IRB of the Mount Sinai School of Medicine (Human Subject no. 18-00427). |
Vol 83 - N° 5
P. 1294-1297 - novembre 2020 Retour au numéro
Article précédent
- Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial
- Amy S. Paller, Elaine C. Siegfried, Diamant Thaçi, Andreas Wollenberg, Michael J. Cork, Peter D. Arkwright, Melinda Gooderham, Lisa A. Beck, Mark Boguniewicz, Lawrence Sher, Jamie Weisman, John T. O'Malley, Naimish Patel, Megan Hardin, Neil M.H. Graham, Marcella Ruddy, Xian Sun, John D. Davis, Mohamed A. Kamal, Faisal A. Khokhar, David M. Weinreich, George D. Yancopoulos, Bethany Beazley, Ashish Bansal, Brad Shumel
- Evaluation of platelet-rich plasma as a treatment for androgenetic alopecia: A randomized controlled trial
- Jerry Shapiro, Anthony Ho, Kumar Sukhdeo, Lu Yin, Kristen Lo Sicco
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?